Pulmonx Corp. (LUNG)

Pulmonx Corp.'s stock price has significantly declined by 81.55% from March 24, 2025, to March 20, 2026. Key events include the release of the Fourth Quarter and Full Year 2025 Financial Results, which led to an 11.81% positive price movement, the release of the Third Quarter 2025 Financial Results, which led to an 18.88% negative price movement, and a management transition announcement, which was followed by a 26.92% positive price movement. Pulmonx added a $60 million loan with Perceptive and issued warrants. Vanguard disclosed zero Pulmonx holdings after an internal realignment, while Soleus group reported holding 2.67 million Pulmonx shares.

Pulmonx's products and services may experience demand seasonality, with possible slowing of demand in the beginning and end of the year, as well as during summer months, due to the elective nature of the procedures. This seasonality may become more pronounced as the business grows.

Pulmonx Corporation is a commercial-stage medical technology company focused on minimally invasive treatments for severe emphysema, a form of COPD. Their products include the Zephyr Valve, a one-way valve implanted in airways to block diseased lung portions; the Chartis Pulmonary Assessment System, a balloon catheter system to assess collateral ventilation; and the LungTraX Platform, a cloud-based CT analysis service with LungTraX Connect, LungTraX Detect, and StratX Lung Analysis Report.

Pulmonx has a global presence with products available in over 25 countries. The United States is a key revenue market, with additional revenue from Europe, the Middle East, Africa, and Asia Pacific.

Pulmonx has a mixed brand perception. The Zephyr Valve has strong clinical validation and acceptance, with FDA breakthrough device designation and inclusion in global treatment guidelines. However, the significant stock price decline and consistent unprofitability suggest investor disappointment, potentially impacting its reputation among investors.

Approximately 64.58% of Pulmonx's stock is owned by institutional investors, 13.71% by insiders, and 21.71% by public companies and individual investors. Major institutional owners include Primecap Management Co/ca/, Morgan Stanley, and BlackRock, Inc. Notable individual and insider owners include Theofanis Kolokotrones and Glendon E. French.